Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Sells $88,503.36 in Stock

Pliant Therapeutics, Inc. (NASDAQ:PLRX) General Counsel Mike Ouimette sold 7,656 shares of Pliant Therapeutics stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $11.56, for a total transaction of $88,503.36. Following the completion of the sale, the general counsel now owns 94,044 shares in the company, valued at $1,087,148.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pliant Therapeutics Stock Up 2.0 %

NASDAQ:PLRX opened at $12.75 on Monday. Pliant Therapeutics, Inc. has a one year low of $10.29 and a one year high of $20.23. The firm’s fifty day moving average price is $12.25 and its two-hundred day moving average price is $14.49. The company has a current ratio of 16.12, a quick ratio of 16.12 and a debt-to-equity ratio of 0.07.

Pliant Therapeutics (NASDAQ:PLRX) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.02). On average, analysts anticipate that Pliant Therapeutics, Inc. will post -3.44 EPS for the current year.

Analyst Ratings Changes

PLRX has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Pliant Therapeutics in a report on Friday, June 7th. Citigroup lowered their target price on shares of Pliant Therapeutics from $45.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, May 7th. Royal Bank of Canada lowered their target price on shares of Pliant Therapeutics from $54.00 to $45.00 and set an “outperform” rating on the stock in a report on Tuesday, May 7th. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Pliant Therapeutics in a report on Tuesday, May 7th. Finally, Oppenheimer boosted their target price on shares of Pliant Therapeutics from $47.00 to $48.00 and gave the stock an “outperform” rating in a report on Tuesday, May 7th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Pliant Therapeutics presently has an average rating of “Buy” and an average price target of $45.38.

Hedge Funds Weigh In On Pliant Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of PLRX. Quest Partners LLC acquired a new position in shares of Pliant Therapeutics in the fourth quarter valued at $37,000. SG Americas Securities LLC bought a new stake in shares of Pliant Therapeutics in the first quarter valued at about $107,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Pliant Therapeutics by 353.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,929 shares of the company’s stock valued at $125,000 after acquiring an additional 5,400 shares during the period. ProShare Advisors LLC boosted its position in shares of Pliant Therapeutics by 9.1% in the first quarter. ProShare Advisors LLC now owns 14,489 shares of the company’s stock valued at $216,000 after acquiring an additional 1,203 shares during the period. Finally, Arizona State Retirement System boosted its position in shares of Pliant Therapeutics by 6.4% in the fourth quarter. Arizona State Retirement System now owns 12,545 shares of the company’s stock valued at $227,000 after acquiring an additional 754 shares during the period. 97.30% of the stock is currently owned by institutional investors and hedge funds.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.